{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:46:38Z","timestamp":1790905598148,"version":"4.1.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA44991"],"award-info":[{"award-number":["CA44991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7040\u201003"],"award-info":[{"award-number":["7040\u201003"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["3100AO\u2010110023\/1"],"award-info":[{"award-number":["3100AO\u2010110023\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003360","name":"Ligue Genevoise Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Learning Objectives<\/jats:title><jats:p>After completing this course, the reader will be able to: Summarize current upfront treatment options in follicular lymphoma.Differentiate biological treatment options with demonstrated efficacy from promising new developments in research and clinical trials.Better understand RIT and its therapeutic promise.<\/jats:p><jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p><jats:p>Advanced-stage follicular lymphoma is incurable by conventional treatment. Rituximab has been introduced in various combinations with chemotherapy and has resulted in a significantly superior treatment outcome compared with chemotherapy alone. Multiple studies have also shown the efficacy of radioimmunotherapy (RIT) both as a single agent and in combination with chemotherapy. Rituximab and RIT have clearly distinct mechanisms of action, the first acting exclusively as a biological treatment, while the second acts by a combination of biologic mechanisms and radiation effects. Despite the therapeutic efficacy of both approaches, the potential exists to further improve both modalities. Repeat administrations of RIT using appropriate radioisotopes for treatment of residual disease or new targeting strategies might afford additional benefits. Unlabeled antibody treatment could potentially benefit from the combination of antibodies directed against different target antigens or combination therapy with cytokines capable of further mobilizing patients' cellular defenses. In this review, we hypothesize that the combination of an optimized biological treatment together with radiolabeled antibodies and chemotherapy early in the disease course of advanced-stage follicular lymphoma may represent the best approach to achieve prolonged disease-free survival and eventually cure.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2008-0020","type":"journal-article","created":{"date-parts":[[2008,6,27]],"date-time":"2008-06-27T15:38:21Z","timestamp":1214581101000},"page":"657-667","source":"Crossref","is-referenced-by-count":19,"title":["Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma"],"prefix":"10.1093","volume":"13","author":[{"given":"Franz","family":"Buchegger","sequence":"first","affiliation":[{"name":"a Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"c Service of Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"a Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"d Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika Bischof","family":"Delaloye","sequence":"additional","affiliation":[{"name":"b Service of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Ketterer","sequence":"additional","affiliation":[{"name":"e Multidisciplinary Oncology Center, University Hospital of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,6,1]]},"reference":[{"key":"2021122208462778100_R1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R2","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R3","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","article-title":"Treatment strategies in follicular lymphomas: Current status and future perspectives","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/01.moh.0000166499.72138.57","article-title":"Transplantation strategies for patients with follicular lymphoma","volume":"12","author":"Buske","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"2021122208462778100_R5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol"},{"key":"2021122208462778100_R6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"2021122208462778100_R7","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.4049\/jimmunol.178.10.6616","article-title":"The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab","volume":"178","author":"Cittera","year":"2007","journal-title":"J Immunol"},{"key":"2021122208462778100_R8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMe048291","article-title":"Radioimmunotherapy\u2014hot new treatment for lymphoma","volume":"352","author":"Connors","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208462778100_R9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-006-0087-6","article-title":"Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies","volume":"6","author":"Dillman","year":"2006","journal-title":"Clin Exp Med"},{"key":"2021122208462778100_R10","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/sj.onc.1210378","article-title":"Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab","volume":"26","author":"Davies","year":"2007","journal-title":"Oncogene"},{"key":"2021122208462778100_R11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1634\/theoncologist.7-3-217","article-title":"Progress and promise in the treatment of indolent lymphomas","volume":"7","author":"McLaughlin","year":"2002","journal-title":"The Oncologist"},{"key":"2021122208462778100_R12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00066-003-1062-8","article-title":"Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma","volume":"179","author":"Ott","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"2021122208462778100_R13","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"2021122208462778100_R14","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"2021122208462778100_R16","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R17","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R18","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"2021122208462778100_R19","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"key":"2021122208462778100_R20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R21","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.2005.05.004","article-title":"Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cncr.20483","article-title":"The role of fludarabine in the treatment of follicular and mantle cell lymphoma","volume":"101","author":"Lenz","year":"2004","journal-title":"Cancer"},{"key":"2021122208462778100_R23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R24","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"67","key":"2021122208462778100_R25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0609.2006.00789.x","article-title":"The therapeutic use of rituximab in non-Hodgkin's lymphoma","author":"Marcus","year":"2007","journal-title":"Eur J Haematol Suppl"},{"key":"2021122208462778100_R26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2006.06378.x","article-title":"Current management of follicular lymphomas","volume":"136","author":"Hiddemann","year":"2007","journal-title":"Br J Haematol"},{"key":"2021122208462778100_R27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122208462778100_R29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.2000.18.5.987","article-title":"Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up\u2014a report from the Eastern Cooperative Oncology Group","volume":"18","author":"Hochster","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R30","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"18 suppl","key":"2021122208462778100_R31","doi-asserted-by":"crossref","first-page":"7502a","DOI":"10.1200\/jco.2006.24.18_suppl.7502","article-title":"Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (RFCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective, randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"24","author":"Dreyling","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11912-007-0051-y","article-title":"Rituximab maintenance in indolent lymphoma: Indications and controversies","volume":"9","author":"van Oers","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"2021122208462778100_R33","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"2021122208462778100_R34","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8 suppl","key":"2021122208462778100_R35","doi-asserted-by":"crossref","first-page":"7534a","DOI":"10.1200\/jco.2006.24.18_suppl.7534","article-title":"A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study","volume":"24","author":"Forero-Torres","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R36","doi-asserted-by":"crossref","first-page":"229a","DOI":"10.1182\/blood.V108.11.229.229","article-title":"Novel 3rd generation humanized type II CD20 antibody with glycoengineered FC and modified elbow hinge for enhanced ADCC and superior apoptosis induction","volume":"108","author":"Umana","year":"2006","journal-title":"Blood"},{"key":"2021122208462778100_R37","doi-asserted-by":"crossref","first-page":"348a","DOI":"10.1182\/blood.V106.11.348.348","article-title":"Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab\u00ae","volume":"106","author":"Weiner","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R38","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1158\/1078-0432.CCR-06-1245","article-title":"Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients","volume":"12","author":"Ansell","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122208462778100_R39","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-06-1571","article-title":"A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma","volume":"12","author":"Khan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122208462778100_R40","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-04-0525","article-title":"Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study","volume":"10","author":"Eisenbeis","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208462778100_R41","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/10428190600565354","article-title":"Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation?","volume":"47","author":"Portlock","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2021122208462778100_R42","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-03-0658","article-title":"Phase I study of rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma","volume":"10","author":"Niitsu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122208462778100_R43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","article-title":"The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma","volume":"20","author":"Van Besien","year":"2006","journal-title":"Blood Rev"},{"key":"2021122208462778100_R44","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"key":"2021122208462778100_R45","first-page":"12","article-title":"Natural killer cells: Biology and clinical use in cancer therapy","volume":"1","author":"Hallett","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"2021122208462778100_R46","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/0008-5472.CAN-06-2283","article-title":"Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res"},{"key":"2021122208462778100_R47","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2004-09-3533","article-title":"An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma","volume":"105","author":"Gillies","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijc.20829","article-title":"Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis","volume":"115","author":"Hombach","year":"2005","journal-title":"Int J Cancer"},{"key":"2021122208462778100_R49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4049\/jimmunol.177.1.306","article-title":"IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb","volume":"177","author":"Kamimura","year":"2006","journal-title":"J Immunol"},{"key":"2021122208462778100_R50","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"2021122208462778100_R51","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1084\/jem.20070543","article-title":"Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo","volume":"204","author":"Kamimura","year":"2007","journal-title":"J Exp Med"},{"key":"2021122208462778100_R52","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo","volume":"177","author":"Stoklasek","year":"2006","journal-title":"J Immunol"},{"key":"2021122208462778100_R53","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1073\/pnas.0600240103","article-title":"Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}","volume":"103","author":"Rubinstein","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208462778100_R54","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122208462778100_R55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122208462778100_R56","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R57","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"2021122208462778100_R58","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"2021122208462778100_R59","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R60","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2004.06.055","article-title":"Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma","volume":"22","author":"Davies","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R61","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/sj.bjc.6603166","article-title":"Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"94","author":"Buchegger","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122208462778100_R62","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"2021122208462778100_R63","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208462778100_R64","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R65","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R66","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14712598.7.11.1749","article-title":"The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas","volume":"7","author":"Jacobs","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"2021122208462778100_R67","doi-asserted-by":"crossref","first-page":"643a","DOI":"10.1182\/blood.V110.11.643.643","article-title":"90Y-Ibritumomab Tiuxetan (Zevalin\u00ae) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: First results of the international randomized phase 3 first-line indolent trial (FIT) in 414 patients","volume":"110","author":"Hagenbeek","year":"2007","journal-title":"Blood"},{"key":"2021122208462778100_R68","doi-asserted-by":"crossref","first-page":"7075s","DOI":"10.1158\/1078-0432.CCR-1004-0008","article-title":"Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies","volume":"11","author":"DeNardo","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2 suppl","key":"2021122208462778100_R69","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ijrobp.2006.06.038","article-title":"Cure of incurable lymphoma","volume":"66","author":"DeNardo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4 suppl","key":"2021122208462778100_R70","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.10304","article-title":"Rationales, evidence, and design considerations for fractionated radioimmunotherapy","volume":"94","author":"DeNardo","year":"2002","journal-title":"Cancer"},{"key":"2021122208462778100_R71","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s00259-006-0187-2","article-title":"Auger radiation targeted into DNA: A therapy perspective","volume":"33","author":"Buchegger","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122208462778100_R72","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/83.9.627","article-title":"Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice","volume":"83","author":"Sharkey","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"2021122208462778100_R73","first-page":"447","article-title":"Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice","volume":"57","author":"Vogel","year":"1997","journal-title":"Cancer Res"},{"key":"2021122208462778100_R74","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"2021122208462778100_R75","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","article-title":"Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group","volume":"24","author":"Chatal","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R76","first-page":"5960","article-title":"Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients","volume":"51","author":"Paganelli","year":"1991","journal-title":"Cancer Res"},{"key":"2021122208462778100_R77","first-page":"406","article-title":"Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody\/streptavidin in patients with metastatic colon cancer","volume":"6","author":"Knox","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122208462778100_R78","first-page":"642","article-title":"Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies","volume":"46","author":"Shen","year":"2005","journal-title":"J Nucl Med"},{"key":"2021122208462778100_R79","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2003-09-3284","article-title":"Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"104","author":"Forero","year":"2004","journal-title":"Blood"},{"key":"2021122208462778100_R80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/cbr.2005.20.185","article-title":"Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma","volume":"20","author":"Wiseman","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"2021122208462778100_R81","first-page":"6663","article-title":"A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy","volume":"60","author":"Schultz","year":"2000","journal-title":"Cancer Res"},{"key":"2021122208462778100_R82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/bc034049g","article-title":"Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma","volume":"16","author":"Hamblett","year":"2005","journal-title":"Bioconjug Chem"},{"key":"2021122208462778100_R83","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/bc010087t","article-title":"A streptavidin-biotin binding system that minimizes blocking by endogenous biotin","volume":"13","author":"Hamblett","year":"2002","journal-title":"Bioconjug Chem"},{"key":"2021122208462778100_R84","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/10428190601059720","article-title":"Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement","volume":"48","author":"Mones","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2021122208462778100_R85","doi-asserted-by":"crossref","first-page":"7146s","DOI":"10.1158\/1078-0432.CCR-1004-0003","article-title":"Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy","volume":"11","author":"Jacobs","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122208462778100_R86","first-page":"30a","article-title":"Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high dose chemotherapy and autologous stem cell transplantation (ASCT)","volume":"102","author":"Vose","year":"2003","journal-title":"Blood"},{"key":"2021122208462778100_R87","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"2021122208462778100_R88","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R89","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R90","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R91","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R92","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.21606","article-title":"Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma","volume":"106","author":"Dosik","year":"2006","journal-title":"Cancer"},{"key":"2021122208462778100_R93","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","article-title":"Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma","volume":"20","author":"Ansell","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R94","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-006-0148-4","article-title":"Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies","volume":"55","author":"Azinovic","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"2021122208462778100_R95","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125C","author":"Jerne","year":"1974","journal-title":"Ann Immunol (Paris)"},{"key":"2021122208462778100_R96","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/j.1460-2075.1982.tb01154.x","article-title":"Recurrent idiotopes and internal images","volume":"1","author":"Jerne","year":"1982","journal-title":"EMBO J"},{"key":"2021122208462778100_R97","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.4049\/jimmunol.144.11.4256","article-title":"Generation of anti-idiotypic and anti-anti-idiotypic monoclonal antibodies in the same fusion. Support of Jerne's Network Theory","volume":"144","author":"Hebert","year":"1990","journal-title":"J Immunol"},{"key":"2021122208462778100_R98","first-page":"152","article-title":"Absorbed fractions for electrons and beta particles in spheres of various sizes","volume":"35","author":"Siegel","year":"1994","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"2021122208462778100_R99","first-page":"13S","article-title":"Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs","volume":"46","author":"de Jong","year":"2005","journal-title":"J Nucl Med"},{"key":"2021122208462778100_R100","doi-asserted-by":"crossref","first-page":"7589a","DOI":"10.1200\/jco.2006.24.18_suppl.7589","article-title":"Imaging results after CHOP-rituximab followed by 90Yibritumomab tiuxetan and rituximab (R) in patients with previously-untreated follicular lymphoma (FL)","volume":"24","author":"Demonaco","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R101","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208462778100_R102","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122208462778100_R103","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"2021122208462778100_R104","doi-asserted-by":"crossref","DOI":"10.1080\/10428190801923725","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume-title":"Leuk Lymphoma","author":"Till","year":"2008"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/6\/657\/41832094\/oncolo_13_6_657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/6\/657\/41832094\/oncolo_13_6_657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:38:32Z","timestamp":1684456712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/6\/657\/6396679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":104,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,6,1]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0020","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,6,1]]},"published":{"date-parts":[[2008,6,1]]}}}